drugset / Trial / NCT05245292
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
Phase 1
Completed
28 enrolled
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID) · collabUniversity of Pennsylvania · collabWeill Medical College of Cornell University · collab
NaSingle-groupOpen-labelTreatment
Summary
The proposed study is a phase 1, open label, single arm study to evaluate the safety and antiretroviral activity of the combination of two long-acting broadly neutralizing antibodies, 3BNC117-LS dosed once at 30 mg/kg and 10-1074-LS dosed once at 10 mg/kg, both intravenously (IV) at week 0, plus an IL-15 superagonist complex, N-803, dosed at 6 mcg/kg, subcutaneously (SC) at week 1 and then every 3 weeks for a total of 8 doses, in ART-treated adults living with HIV during analytical treatment interruption.
Timeline
- Start
- 2022-12-07
- Primary completion
- 2025-12-09
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-803 | Protein / enzyme biologic | 6 ug/kg | Subcutaneous |
| Subject | Teropavimab | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | Zinlirvimab | Monoclonal antibody | 10 mg/kg | Intravenous |